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Objective. To identify the epitopes recognized by autoantibodies targeting platelet-derived growth factor receptor a (PDGFRa) in systemic sclerosis (SSc) and develop novel assays for detection of serum antiPDGFRa autoantibodies.
Methods. Epstein-Barr virus-immortalized B cells from 1 patient with SSc (designated PAM) were screened for expression of IgG binding to PDGFRa and induction of reactive oxygen species in fibroblasts. The variable regions of anti-PDGFRa IgG were cloned into an IgG expression vector to generate distinct recombinant human monoclonal autoantibodies (mAb), which were characterized by binding and functional assays. The epitopes of anti-PDGFRa recombinant human mAb were defined by molecular docking, surface plasmon resonance binding assays, screening of a conformational peptide library spanning the PDGFRa extracellular domains, and expression analyses of alanine-scanned PDGFRa mutants. Direct or competitive enzyme-linked immunosorbent assays were established to detect all serum anti-PDGFRa autoantibodies or, selectively, the agonistic ones.
Results. Three types of anti-PDGFRa recombinant human mAb, with the same V H but distinct V L chains, were generated. Nonagonistic V H PAM-V k 13B8 recognized 1 linear epitope, whereas agonistic V H PAM-V l 16F4 and V H PAM-V k 16F4 recognized 2 distinct conformational epitopes. Serum anti-PDGFRa antibodies were detected in 66 of 70 patients with SSc, 63 of 130 healthy controls, 11 of 26 patients with primary Raynaud's phenomenon (RP), and 13 of 29 patients with systemic lupus erythematosus (SLE). Serum V H PAM-V k 16F4-like antibodies were found in 24 of 34 patients with SSc, but not in healthy controls, patients with primary RP, or patients with SLE. Peptides composing the V H PAM-V k 16F4 epitope inhibited PDGFRa signaling triggered by serum IgG from SSc patients.
Conclusion. Agonistic anti-PDGFRa autoantibodies are enriched in SSc sera and recognize specific conformational epitopes that can be used to discriminate agonistic from nonagonistic antibodies and block PDGFRa signaling in patients with SSc.
Systemic sclerosis (SSc; scleroderma) is a clinically heterogeneous disease of the connective tissue characterized by vascular, immune/inflammatory, and fibrotic manifestations, in which oxidative stress is a prominent feature (1, 2) . Despite extensive investigations, the key pathogenic links between these disease hallmarks remain obscure, which hampers the development of tools for early diagnosis, adequate disease monitoring, and effective therapies. We have previously reported the presence of agonistic anti-platelet-derived growth factor receptor (anti-PDGFR) autoantibodies that stimulate reactive oxygen species (ROS) in the serum IgG of 46 patients with SSc (3). However, other studies (4, 5) failed to detect these stimulatory antibodies in the serum, and found nonstimulatory anti-PDGFR antibodies both in SSc patients and in healthy controls (5) or in patients with systemic lupus erythematosus (SLE) (6) . Therefore, the presence of stimulatory anti-PDGFR autoantibodies in SSc remains controversial (7) .
To address this issue, we generated combinatorial monoclonal autoantibodies (mAb) using immunoglobulin sequences, identified in memory B cells obtained from the peripheral blood of 1 patient with SSc, that were specific for PDGFRa, the isoform that was reported to better discriminate SSc IgG from healthy control IgG (3) . With the use of these reagents, we obtained a novel map of the functional epitopes of PDGFRa selectively driving oxidative stress and collagen gene expression increase. Moreover, we assessed the clinical relevance of these findings by developing novel binding assays for anti-PDGFRa autoantibodies.
MATERIALS AND METHODS
Ethics statements. Use of human material was approved by the Institutional Ethics Committee of Universit a Politecnica delle Marche (Ancona, Italy). Informed consent was obtained from all subjects participating in this study. All assays were performed in a blinded manner on coded samples.
Screening of immortalized memory B cells. CD22-positive memory B cells were purified by magnetic selection (Miltenyi Biotech) from peripheral blood mononuclear cells (PBMCs) obtained from 1 patient with diffuse SSc designated PAM (47-year-old woman with esophagus and lung involvement, a Rodnan skin thickness score of 17, positivity for antinuclear antibodies and anti-Scl-70 antibodies, and negativity for anticentromere antibodies) (8) . These cells (designated the PAM B cells) were immortalized using Epstein-Barr virus, as described previously (9) (10) (11) . Three days postinfection, the cells were manually counted and seeded (5 cells/well) in 96-well plates in the presence of irradiated (30 Gy) allogenic PBMCs. After 2 weeks, B cell supernatants were screened for the presence of anti-PDGFRa antibodies by immunofluorescence and flow cytometry, using, as target cells, mouse embryonic fibroblasts derived from PDGFR-knockout mice (F 2/2 cells) or mouse embryonic fibroblasts transfected with full-length human PDGFRa (Fa cells) (12), as described previously (3) .
Generation of recombinant human mAb. Total RNA was extracted from each anti-PDGFRa-positive B cell line (;300,000 cells) with an RNeasy Micro kit and reversetranscribed with an Omniscript RT kit (Qiagen). Complementary DNA (cDNA) was amplified with polymerase chain reaction (PCR) primers specific for rearranged human IgG variableregion and constant-region heavy-and light-chain genes (13) (details available upon request from the corresponding author). Amplified heavy-and light-chain variable regions (V H and V L , respectively) were sequenced using a TOPO TA Cloning kit (Invitrogen). The unique V H -chain sequence and the 4 different V L -chain sequences amplified in the 3 PAM B cell lines showing PDGFRa binding were alternatively paired to replace the V H and V L chains of antibody b12 (14) , thereby generating 4 distinct human IgG1 constructs. V H and V L sequences were fused with the respective leader peptide sequences using a 3-step overlap extension PCR (15) , and then independently inserted into the Xba I-Sac I and Hind III-Eco RI restriction sites of the pDR12 vector containing the parental human IgG1 constant-region heavy-and light-chain genes, including the Fc sequence.
Upon sequencing, the constructs were stably transfected into Chinese hamster ovary (CHO) cells with Lipofectamine 2000 (Invitrogen). Expression of recombinant IgG in the culture supernatants was confirmed by human IgG-specific enzyme-linked immunosorbent assay (ELISA). Cell cultures were expanded in bioreactors (CELLine CL-1000; Integra Biosciences), and secreted recombinant human mAb were purified from the supernatants by Protein A-affinity and size-exclusion chromatography. The purity of the recombinant human mAb was checked by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) Coomassie brilliant blue protein staining.
Immunoprecipitation and immunoblotting. Each recombinant human mAb (10 mg/ml) was incubated for 4 hours at 48C with 100 mg of total protein extracts from human fibroblasts. The mixture was incubated overnight at 48C with 20 ml of agarose-Protein A/G (Santa Cruz Biotechnology). The immunocomplexes were then subjected to SDS-PAGE and immunoblotting, as described previously (3) .
Functional assays. Primary human fibroblasts from adult healthy skin (Life Technologies) were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum (FCS) for 2 passages. When subconfluence was reached, the cells were maintained in 0.2% FCS for 24 hours, before the addition of human PDGF-BB (15 ng/ml), transforming growth factor b (2 ng/ml) (each from R&D Systems), or recombinant human mAb (10 mg/ml). Protein extracts (30 mg) were separated on 4-12% SDS-PAGE under reducing conditions and transferred to PVDF membranes. After blocking, the membranes were probed with anti-pAkt (sc-439), anti-pERK-1/2 (sc-7783), and anti-Ha-Ras (sc-520) antibodies, and then stripped and reprobed with antibodies to total Akt, ERK-1/2, and b-actin (Santa Cruz Biotechnology), followed by horseradish peroxidase (HRP)-conjugated antibodies.
To quantify collagen gene transcription, total RNA was extracted from the primary human fibroblasts using the Aurum total RNA Mini kit (Bio-Rad) at baseline and after 1 The ROS bioassay was performed as described previously (3, 16) , using a fluorometric assay to determine the amount of intracellular ROS generated by adherent fibroblasts.
Homology modeling and molecular docking. Homology modeling to predict the unknown 3-dimensional structures of human PDGFRa and recombinant human mAb monovalent fragments from their amino acid sequences was performed using a Swiss-Model server (17) . Swiss-Pdb Viewer software was used to create project files submitted to the server with default parameter settings (BLAST search P , 0.00001 and global degree of sequence identity .25% determined using the SIM alignment tool). PDGFRa query sequences were obtained from the UniProt Knowledgebase (details available at http:// beta.uniprot.org/). Rigid protein-protein molecular docking between homology-modeled monomeric PDGF-BB (pdb identification no. 1PDG) (18) , recombinant human mAb Fab fragments, and monomeric PDGFRa was performed by uploading the pdb files on a ClusPro 2.0 server (19) and using DOT software (version 1.0) as the docking program, with a clustering radius of 5Å , electrostatic hits of 1,500, and 30 final resulting structures (details available upon request from the corresponding author).
Generation and screening of PDGFRa peptide library. Eighty overlapping 15-oligomer synthetic peptides spanning the first 3 N-terminal, extracellular Ig-like domains of PDGFRa were flanked by either glycines or cysteines. Glycine-flanked peptides were left in linear conformation, whereas cysteine-flanked peptides were imposed on a trivalent (T3) chemical scaffold containing (20, 21) , the eighty 15-oligomer segments were all combined with each other to obtain all of the possible combinations of Cys-15-oligomer-Cys-15-oligomer-Cys bicyclic peptides (total number of 30-oligomer peptides identified by T3-CLIPS 5 6,400). The T3-CLIPS topology allows the peptides to have either a 2-looped folding or a loop plus partial sheet folding. The combinatory peptides were immobilized onto 455-well plates, and binding of recombinant human mAb and PDGF-BB was tested by Pepscan-based ELISA (Pepscan Therapeutics).
Soluble peptides. Three peptides were synthesized and numbered from 1 to 3 following the amino acid sequence of human extracellular PDGFRa from the N-to the C-terminus. Peptide 1 was ac-VIVEDDDSAIIPCRTTD-conh2, peptide 2 was ac-VVPASYDSRQGFNGTFTVGPYICE-conh2, and peptide 3 was ac-CAARQATREVKEMKKVT-conh2. Scrambled peptide 2 was ac-IASGCGTFTRVVFEQPNSPYYDGV-conh2. The purity of the peptides, determined by high-performance liquid chromatography, was .95%.
In binding-competition experiments, V H PAM-V k 16F4 (10 mg/ml) (molar ratio of peptide to recombinant human mAb 100:1) or a pool of IgG from the serum of 6 SSc patients or 6 healthy controls (each 200 mg/ml) was incubated in solution with single peptides for 1 hour at 378C. The mixtures were then used to stimulate fibroblasts.
PDGFRa mutagenesis and expression of PDGFRa mutants in F 2/2 mouse embryonic fibroblasts. Five different sets of alanine mutations were introduced into the epitope of V H PAM-V k 16F4. The template for mutagenesis (GenScript) was the full-length human PDGFRa cDNA inserted into the retroviral vector pLHDCX2 (22) . The PDGFRa mutants were termed Ala-scans and numbered from the N-to the C-terminus according to the corresponding peptides: for . Two longer Ala-scans were generated, combining Ala-scans 1 and 2 (Ala-scan 4) or Ala-scans 1, 2, and 3 (Ala-scan 5). The 5 Ala-scans were individually transfected into PA317 cells (ATCC) with Lipofectamine, to produce retroviral virions (23) . Virus-containing medium was collected, concentrated (at 25,000g for 90 minutes at 48C), and used to infect F 2/2 mouse embryonic fibroblasts (12) grown in DMEM with 8 mg/ml polybrene (hexadimethrine bromide; Sigma-Aldrich) for 24 hours. Successfully infected cells were selected in histidine-free DMEM containing 5 mM histidinol (Sigma-Aldrich) (24) . Mutated PDGFRa expression was assessed in the cells by fluorescence-activated cell sorting analysis, using V H PAM-V k 16F4 and anti-PDGFRa mAb 1264 antibodies (R&D Systems).
Immunoenzymatic assays (ELISAs). A recombinant receptor fused to a poly-histidine tag (PDGFRa-His), either produced in-house (25) or obtained commercially (amino acid Met-1-Glu-524, code no. 10556-H08H; Sino Biological), was immobilized (0.5 mg/ml in 100 ml HEPES buffered saline [HBS], pH 7.2) onto 96-well Nunc Maxisorp ELISA plates overnight at 48C. After 2 hours of blocking at 378C with 200 ml of HBS containing 0.2% polyvinylpyrrolidone (Sigma-Aldrich) and washing with HBS/0.05% Tween 20, serum (1:100 in HBS, 100 ml/well) was added overnight at 48C. After extensive washing, HRP-conjugated anti-human IgG (1:10,000, 100 ml/well) (Jackson ImmunoResearch) was added for 1 hour at 208C. The reaction was developed with 100 ml of tetramethylbenzidine (BioFX) for 10 minutes at room temperature, and then stopped with 50 ml of 0.5M H 2 SO 4 . The optical density (OD) was measured at 450 nm.
In the peptide-based ELISA, 20 mg/ml of each peptide was immobilized onto 96-well plates and probed with 0.7 mg/ml of the indicated recombinant human mAb. In the competitive ELISA, serum (1:100), V H PAM-V k 16F4 (0.7 mg/ml), or PDGF-BB (15 ng/ml) was preincubated with 25 mg/ml of the indicated peptide (molar ratio of peptide to PDGFRa 50:1) for 1 hour at 378C. Alternatively, serum (1:100) was incubated with immobilized PDGFRa-His overnight at 48C, before adding biotinylated V H PAM-V k 16F4 (100 ng/ml) (ChromaLink Biotin Protein Labeling Kit Solulink; VWR International) for 2 hours at 378C, followed by HRP-conjugated streptavidin (1:5,000) (Bio-Rad) for 1 hour at room temperature.
Statistical analysis. Data are presented as the mean 6 SEM or mean 6 SD, as indicated. Results were analyzed with one-way analysis of variance for nonparametric data, with a Kruskal-Wallis test and Dunn's test for multiple comparisons (analyses of peptide binding, direct and competitive ELISAs) or 2-tailed unpaired t-test (with 95% confidence intervals [95% CIs]) (functional analyses, cell-based assays). Spearman's rank correlation coefficients (for nonparametric data) were calculated to assess correlations between the percentage of inhibition of V H PAM-V k 16F4 binding to PDGFRa-His after incubation with sera, and the percentage of inhibition of serum binding to PDGFRa after preincubation with peptide 2. Receiver operating characteristic (ROC) curves were generated to determine the area under the ROC curve with its 95% CI. The optimal cutoff values were chosen according to the highest Youden index, representing sensitivity 1 (1 2 specificity), which was calculated using MedCalc12 software. GraphPad Prism 5 and MedCalc12 software were used for all statistical analyses. P values less than 0.05 were considered statistically significant.
RESULTS
Cloning of agonistic and nonagonistic antiPDGFRa autoantibodies from the memory B cells of a patient with SSc. Immortalized memory B cells from 1 patient with SSc (the PAM B cell lines) (9-11) were seeded in 96-well plates. Supernatants of ;2,000 wells were screened for the presence of IgG selectively binding to Fa mouse embryonic fibroblasts, but not to fibroblasts derived from F 2/2 mouse embryos (12) , and inducing ROS in the fibroblasts. Three B cell cultures (namely, PAM13B8, PAM16F4, and PAM17H8) contained PDGFRa-binding IgG, of which the IgG from PAM16F4 B cells induced ROS ( Figure 1A) .
RNA was extracted from these B cells, reversetranscribed, and amplified with primers designed to analyze the human IgG gene repertoire (13) . PCR analysis of rearranged IgG genes suggested the presence of a panel of V H and V L chains representative of most IgG subgroups ( Figure 1B) . However, subsequent sequencing revealed that most of these PCR products were similar, although not identical, at the oligonucleotide level (details available upon request from the corresponding author), both within each of the individual B cell cultures and among the 3 cell cultures, indicating that oligoclonal restriction occurred. Indeed, PAM13B8, PAM16F4, and PAM17H8 cells shared a single V H -chain amino acid sequence, designated V H PAM, and a V L chain, designated V l 13B8. Moreover, PAM13B8 and PAM17H8 shared a V k chain, designated V k 13B8, whereas the repertoire of PAM16F4 included 2 additional V L chains, designated V k 16F4 and V l 16F4 ( Figure 1B) .
The V H PAM cDNA and, alternatively, each of the 4 V L PAM cDNAs were cloned into an expression vector containing the human IgG1 constant region (15) and transfected into CHO cells to produce 4 recombinant human mAb, designated V H PAM-V k 13B8, V H PAM-V l 13B8, V H PAM-V k 16F4, and V H PAM-V l 16F4. All recombinant human mAb, except V H PAM-V l 13B8, immunoprecipitated PDGFRa from human fibroblast lysates ( Figure 1C) . V H PAM-V k 16F4 and V H PAM-V l 16F4, but not V H PAM-V k 13B8 and V H PAM-V l 13B8, induced ROS production and phosphorylation of ERK-1/2 and Akt in vitro ( Figure 1D ). V H PAM-V k 16F4, but not V H PAM-V l 16F4, also induced Ha-Ras and type I collagen gene expression ( Figure 1D ). These data show that PDGFRa binding and the biologic effects of these recombinant human mAb can be dissociated, suggesting that the PDGFRa epitopes mediating such functions are distinct.
Epitope mapping of human PDGFRa. To identify the PDGFRa-specific epitopes of the recombinant human mAb, we used in silico molecular docking, i.e., a computer simulation of molecular interactions, as a starting model to predict the binding regions between homology-modeled monomeric human PDGFRa and recombinant human mAb Fab fragments or monomeric human PDGF-BB, the only PDGF isoform with resolved crystal structure. PDGF-BB was predicted to bind a discontinuous epitope encompassing 4 amino acid segments lying between the second and third Ig-like extracellular domains of PDGFRa (Figure 2A) , which is consistent with the observations from previous studies (26, 27) .
The agonistic recombinant human mAb V H PAM-V k 16F4 was predicted to bind to a discontinuous epitope within the second and third PDGFRa extracellular domains, largely overlapping the PDGF-BB binding site ( Figure 2B) . Conversely, the predicted epitope of the nonagonistic recombinant human mAb V H PAM-V k 13B8 encompassed a single linear amino acid sequence within the first PDGFRa extracellular domain ( Figure 2C ). Part of this sequence was shared by the larger, discontinuous epitope of the agonistic recombinant human mAb V H PAM-V l 16F4, which comprised additional amino acid stretches in the first and second PDGFRa domains ( Figure 2D ).
To experimentally validate these predictive data, we screened with PDGF-BB and the recombinant human mAb a conformational PDGFRa peptide library, which was synthesized by Pepscan (28, 29) . This approach highlighted a remarkable correspondence between the predicted (in silico) and the actual (in vitro) PDGFRa epitopes bound by the recombinant human mAb and by PDGF-BB (Figures 2A-C) , except V H PAM-V l 16F4, which did not bind to any peptide, most likely because of an incomplete representation of its conformational epitope in the library. Notably, the highest binding peaks of PDGF-BB and V H PAM-V k 16F4 occurred with looped peptides (results available upon request from the corresponding author), corroborating the conformational nature of their PDGFRa epitopes.
To further validate the PDGFRa epitope mapping, binding-competition experiments were performed on a surface plasmon resonance device, in which the PDGFRa-His, immobilized and folded into a native-like conformation (25) , was saturated with PDGF-BB or a single recombinant human mAb before each recombinant human mAb was added. The resulting sensorgrams ( Figures 2B-D, insets) showed that binding of V H PAM-V k 16F4 to PDGFRa was completely prevented by PDGF-BB, but only partially prevented by V H PAM-V k 13B8 (Figure 2B ), likely because of steric hindrance. Saturation with V H PAM-V l 16F4 only slightly inhibited binding of V H PAM-V k 16F4 to PDGFRa ( Figure 2B ). These data confirm that V H PAM-V k 16F4 (inducing both ROS and type I collagen genes) recognizes an epitope that overlaps the PDGF binding site but is distinct from the epitopes of V H PAM-V k 13B8 (nonagonistic) and V H PAM-V l 16F4 (inducing ROS, but not type I collagen genes). Conversely, binding of V H PAM-V k 13B8 and V H PAM-V l 16F4 to PDGFRa was not significantly inhibited by PDGF-BB (Figures 2C and D) . Moreover, V H PAM-V k 13B8 and V H PAM-V l 16F4 showed partial reciprocal binding inhibition ( Figures 2C and D) , consistent with the minimal overlap between their epitopes.
We therefore conclude that there are 3 distinct PDGFRa epitopes recognized by these antibodies. One epitope, largely shared by PDGF-BB and by the ROSand collagen-inducing V H PAM-V k 16F4, is conformational and discontinuous. The second epitope, bound by V H PAM-V l 16F4 and inducing ROS but not collagen, is also conformational and discontinuous. The third epitope, bound by V H PAM-V k 13B8, is an apparently nonfunctional single peptide in the first extracellular domain of PDGFRa.
Interference of specific PDGFRa peptides with the binding and functions of V H PAM-V k 16F4 recombinant human mAb and serum IgG from SSc patients. The 3 peptides corresponding to the PDGFRa sequences ( Figure 2B ), composing the discontinuous epitope Figure 3A) . Preincubation with any of these peptides significantly inhibited V H PAM-V k 16F4 binding to PDGFRa ( Figure 3B ) and V H PAM-V k 16F4-mediated collagen gene induction ( Figure 3C ). Peptide 2 was the most effective inhibitor under these experimental conditions, as it also significantly reduced PDGF-BB binding ( Figure 3B ) and collagen gene induction and ROS production triggered by SSc IgG ( Figure 3D ). Peptide 1, but not peptide 3, inhibited SSc IgG-induced ROS production ( Figure 3D ). The scrambled peptide 2 did not bind to V H PAM-V k 16F4, PDGF-BB, or SSc IgG, nor did it inhibit their agonistic effects ( Figures  3A-D) .
Mutagenesis of the discontinuous epitope of the agonistic recombinant human mAb V H PAM-V k 16F4. A limited alanine-scanning mutagenesis of the essential motifs composing the V H PAM-V k 16F4 epitope ( Figures  2B and 4A ) was performed. Binding to V H PAM-V k 16F4 was retained by Ala-scans 1, 2, and 3 ( Figure 4B) ; however, COL1A1 gene stimulation by V H PAM-V k 16F4 was observed with Ala-scans 1 and 3 only, whereas it was completely impaired by Ala-scan 2 ( Figure 4C ). This result is consistent with the finding that peptide 2 is the most effective inhibitor of V H PAM-V k 16F4-induced , and Ala-scan-expressing cells exposed to V H PAM-V k 16F4 for 1 hour. Values are the mean 6 SEM relative fold increase in expression, calculated by the 2 2DDCt method, in 3 experiments performed in duplicate, normalized to the mean values of endogenous cyclophilin A. * 5 P , 0.05 versus baseline. FITC 5 fluorescein isothiocyanate; PE 5 phycoerythrin (see Figure 1 for other definitions).
collagen stimulation ( Figure 3C ) and indicates that the TFT amino acid motif is essential for collagen induction.
Expression of Ala-scan 4, spanning motifs 1 and 2, or Ala-scan 5, spanning motifs 1, 2, and 3 ( Figure  4A ), impaired both V H PAM-V k 16F4 binding and collagen gene stimulation ( Figures 4B and C) . These results independently validate the findings from PDGFRa epitope mapping, and highlight the minimal extracellular PDGFRa motif required for collagen gene stimulation.
Detection of anti-PDGFRa autoantibodies in the serum of SSc patients. Three independent assays were established to detect anti-PDGFRa autoantibodies in the serum of SSc patients. The first was a direct ELISA with PDGFRa-His immobilized onto 96-well plates. We tested serum samples from 70 consecutive patients with a definite diagnosis of SSc (8) (details on the patients' clinical data are available upon request from the corresponding author), from 130 sex-and agematched healthy control subjects, and from 26 consecutive patients with a definite diagnosis of primary Raynaud's phenomenon (RP) (30) . Based on the optimal OD cutoff value for autoantibody positivity, as determined by ROC curve analysis of SSc and healthy control serum, 94.3% of SSc patients (66 of 70 patients), 48.5% of healthy controls (63 of 130 subjects), and 42.3% of patients with primary RP (11 of 26 patients) were positive for anti-PDGFRa autoantibodies (P , 0.0001 between SSc patients and the other groups) ( Figure  5A ). Similar results were obtained using a commercial PDGFRa-His (results available upon request from the corresponding author), thus ruling out the possibility of Figure 5 . Detection of serum anti-platelet-derived growth factor receptor a (anti-PDGFRa) autoantibodies. A, Left, Direct enzyme-linked immunosorbent assay (ELISA) of anti-PDGFRa autoantibodies in serum from patients with systemic sclerosis (SSc), healthy control (HC) subjects, and patients with primary Raynaud's phenomenon (PRP). The optimal cutoff value for PDGFRa binding between positive and negative sera is indicated by the broken line. Right, The optimal cutoff for binding was determined by receiver operating characteristic (ROC) curve analyses of the area under the ROC curve (AUC) for SSc patients versus healthy controls (sensitivity 94.4%, specificity 51.5%, AUC 0.801 [95% confidence interval 0.793-0.854]). B, Left, Inhibition of binding of SSc serum to PDGFRa by peptide 2. The optimal cutoff value for discriminating sera whose binding to PDGFRa is significantly inhibited by peptide 2 is indicated by the broken line. Right, The optimal cutoff for inhibition was determined by ROC curve analyses (sensitivity 70.6%, specificity 88.2%, AUC 0.764 [95% confidence interval 0.645-0.858]). C, Left, Binding inhibition of V H PAM-V k 16F4 to PDGFRa by sera. The optimal cutoff value for discriminating sera inhibiting V H PAM-V k 16F4 binding to PDGFRa from those weakly or not providing inhibition is indicated by the broken line. Right, The optimal cutoff for inhibition was determined by ROC curve analyses (sensitivity 70.6%, specificity 94.1%, AUC 0.760 [95% confidence interval 0.641-0.856]). D, Direct ELISA or competitive ELISAs (with peptide 2 or scrambled peptide 2 control) of SLE serum. Each dot represents the mean optical density of each sample from triplicate experiments. Symbols indicate individual samples; horizontal line indicates the median. ** 5 P , 0.001; *** 5 P , 0.0001, versus SSc serum. * Human IgG (200 mg/ml) was purified from the serum of 24 patients with systemic sclerosis (SSc) tested for binding to platelet-derived growth factor receptor a (PDGFRa) on both direct and competitive enzymelinked immunosorbent assays (ELISAs), the serum of 4 SSc patients testing negative for anti-PDGFRa autoantibodies on direct ELISA, and the serum of 26 healthy control subjects, of which 24 were positive and 2 were negative for anti-PDGFRa on direct ELISA. All IgG samples were tested for their ability to induce production of reactive oxygen species (ROS) in mouse embryonic fibroblasts transfected with full-length human PDGFRa. Except where indicated in boldface, values were above the cutoff for positivity. In direct ELISA, the cutoff for binding was an OD value of 0.129. In competitive ELISA, the cutoff for inhibition was 29.8%. In the ROS assay, the cutoff for positivity was a stimulation index (SI) of 0.4, calculated as SI 5 (S 2 C) 4 (P 2 C), where S is the dihydrodichlorofluorescein diacetate (DCFH-DA) fluorescence intensity of the test IgG, C is the DCFH-DA fluorescence intensity of a negative control obtained by culturing cells without IgG, and P is the DCFH-DA fluorescence intensity of a positive control obtained by incubating cells with PDGF-BB (15 ng/ml for 15 minutes). Samples able to induce ROS were tested in the presence of the PDGFRa inhibitor AG1296 (2 mM).
EPITOPE SPECIFICITY OF ANTI-PDGFRa AUTOANTIBODIES IN SSc
any artificial binding of serum IgG to the PDGFRa-His that was produced in-house. None of the serum samples showed nonspecific binding to uncoated plates (results not shown).
The second assay was a competitive ELISA between immobilized PDGFRa-His and peptides covering the V H PAM-V k 16F4 epitope. To evaluate the presence of serum anti-PDGFRa IgG recognizing the same epitope of the agonistic recombinant human mAb V H PAM-V k 16F4, sera from patients with SSc and healthy controls (each n 5 34) and from patients with primary RP (n 5 18), chosen on the basis of homogeneous frequency distribution of OD values (as determined in the first assay), were incubated with peptide 2 (the most effective inhibitor of the stimulatory effects of V H PAM-V k 16F4 and SSc IgG [ Figures 3B-D] ) before binding to immobilized PDGFRa. Based on the optimal cutoff value for inhibition determined on the ROC curve, preincubation with peptide 2 significantly inhibited PDGFRa binding of 70.6% of SSc serum samples (24 of 34 patients) compared with 11.7% of healthy control serum samples (4 of 34 subjects; P , 0.001) and none of the primary RP serum samples (P , 0.0001) ( Figure 5B ). Similar results were obtained when the assay was repeated with peptide 1, whereas peptide 3 was less efficient, inhibiting binding of 50% of SSc sera (17 of 34 patients), 8.8% of healthy control sera (3 of 34 subjects), and none of the primary RP sera (results available upon request from the corresponding author).
To confirm that inhibition was due to specific binding of peptide 2 to serum IgG, the assay was repeated using IgG purified from 8 of 24 autoantibodypositive SSc serum samples and from all 4 autoantibodypositive healthy control serum samples. While binding of SSc IgG was inhibited by peptide 2, binding of IgG from healthy control serum was no longer inhibited (results available upon request from the corresponding author). These findings suggest that there are serum components mediating the binding of healthy control serum to peptide 2.
The third assay was a competitive ELISA between serum and V H PAM-V k 16F4. To confirm that SSc sera contain autoantibodies similar to V H PAM-V k 16F4, the same SSc patient serum samples as tested in the second assay were incubated onto immobilized PDGFRa-His before biotinylated V H PAM-V k 16F4 was added. The 24 of 34 SSc serum samples previously shown to be inhibited by peptide 2 significantly diminished V H PAM-V k 16F4 binding to PDGFRa. Only 2 (5.9%) of 34 healthy control serum samples and 2 (11.1%) of 18 primary RP serum samples inhibited binding ( Figure 5C ). Spearman's rank correlation analyses indicated that in the 2 competitive ELISAs with the SSc serum (P , 0.0001, r 5 0.678), but not those with the healthy control serum (P 5 0.403, r 5 20.147) or primary RP serum (P 5 0.668, r 5 20.108), the results were statistically significantly associated.
Finally, direct and competitive ELISAs were performed with serum samples from 29 consecutive patients with SLE (SLE Disease Activity Index range [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The distribution of PDGFRa binding in SLE serum was comparable to that in healthy control serum, as determined by direct ELISA with PDGFRa-His. Moreover, this was not influenced by the extent of disease activity or peptide 2 competition ( Figure 5D ).
Comparison between ELISA and ROS assays. IgG purified from the serum of 24 of 34 SSc patients analyzed for PDGFRa binding by the direct and competitive ELISAs ( Figures 5A and B) and from 4 SSc serum samples found negative for anti-PDGFRa on the direct ELISA ( Figure 5A ) were tested by ROS assay (3) ( Table 1 ). All sera found positive for anti-PDGFRa autoantibodies by direct ELISA, including 16 samples found positive and 8 found negative by the competitive ELISA, contained ROS-inducing IgG, except SSc serum sample 24, which was negative on the competitive ELISA. Conversely, the 4 sera (samples [25] [26] [27] [28] found negative on the direct ELISA did not contain ROSinducing IgG.
The ROS-inducing activity of the 7 samples negative for anti-PDGFRa on the competitive ELISA (i.e., not containing antibodies with the same specificity of V H PAM-V k 16F4) was abolished by the PDGFRa tyrosine kinase inhibitor AG1296, further suggesting that V H PAM-V k 16F4-like IgG is not the only agonistic antiPDGFRa autoantibody species. Healthy control serum positive for IgG binding to PDGFRa on the direct ELISA did not induce ROS, except samples 25 and 26, which induced ROS through a PDGFR-independent mechanism, since ROS production was unaffected by the PDGFRa inhibitor AG1296 (Table 1) .
DISCUSSION
Human PDGFRa has been implicated in a variety of diseases, including cancer, atherosclerosis, and fibrosis (31) (32) (33) ; however, the PDGFRa domains critical for disease pathogenesis are not completely defined. In vitro mutagenesis (26) and crystallographic studies (34) have indicated that the amino acid residues involved in receptor binding by PDGF are located in the Ig-like extracellular domains 1, 2, and 3. The recombinant human mAb generated from PDGFRa-specific memory B cells obtained from 1 patient with SSc extend this information by identifying regions of the receptor that transduce signals to NADPH oxidase (35, 36) and to collagen genes (37) . These regions can either largely overlap the canonical PDGF binding site (epitope of V H PAM-V k 16F4) or be distinct from it (epitope of V H PAM-V l 16F4). The findings suggest that these different PDGFRa motifs, when stimulated, modulate local and/or long-distance propagation of signals of the activated receptor that selectively govern complex phenotypes, such as fibrosis and oxidative stress (38) .
This study reconciles the controversial results concerning the existence of stimulatory anti-PDGFR antibodies in SSc (4, 5) . First, our findings demonstrate that stimulatory and nonstimulatory anti-PDGFRa autoantibodies may coexist in the same SSc patient. Second, stimulatory anti-PDGFRa autoantibodies recognize specific conformational epitopes, which must be preserved in binding assays to discriminate agonistic from total antibodies, and can be mimicked by specific peptides. Third, stimulatory anti-PDGFRa autoantibodies specific for these conformational epitopes are enriched in the serum of SSc patients. Moreover, the comparison between the ROS bioassay (3) and the peptide-based competitive ELISA described herein, both performed with the same SSc and healthy control sera used in this study (although performed with a limited number of samples), indicated a remarkable concordance.
The discordant results, i.e., the 7 SSc serum samples testing negative by competitive ELISA but positive by ROS bioassay, can also be meaningfully interpreted. Indeed, these samples became unable to induce ROS in the presence of a specific PDGFR tyrosine kinase inhibitor, which demonstrates that they contain agonistic PDGFRa-specific antibodies. These antibodies differ from V H PAM-V k 16F4, since they were not inhibited by peptide 2. It is tempting to speculate that they are similar to V H PAM-V l 16F4, the other agonistic antibody cloned from the PAM B cells.
The presence of different agonistic PDGFRaspecific antibodies, binding distinct epitopes, may account for the lower sensitivity of the competitive ELISA, which was based on one epitope, as compared to the ROS bioassay. Notably, the combined analysis of antibody binding and ROS production highlighted the existence of a subgroup of SSc patients in whom stimulatory anti-PDGFRa IgG was absent. This group was not previously identified in the small SSc cohort in whom only ROS activity was measured (3). Nonstimulatory anti-PDGFRa antibodies have been identified by other investigators in studies of SSc and SLE patients and healthy controls (5, 6) . Our data confirm these findings, and indicate that complete discrimination between nonagonistic and agonistic autoantibodies can be achieved only by a combination of epitope-based binding assays and functional assays. Of note, IgG purified from the serum of 2 healthy control subjects and 2 patients with primary RP that inhibited binding of biotinylated V H PAM-V k 16F4 to PDGFRa did not induce ROS (results available upon request from the corresponding author).
The assessment of the diagnostic relevance of stimulatory anti-PDGFRa antibodies, i.e., their efficacy in discriminating patients affected by early-stage SSc from patients affected by related conditions such as primary RP, will require the prospective screening of large cohorts of patients suspected of having SSc (39), whose serum should be assessed by optimized peptide-based assays. Moreover, the longitudinal analysis of agonistic anti-PDGFRa antibodies during disease progression will indicate their potential usefulness as a biomarker of SSc (40) . Notably, the 24 patients with SSc whose serum tested positive for anti-PDGFRa on both competitive ELISAs had a more severe disease phenotype compared with the 10 SSc patients whose serum tested negative, but this observation must be confirmed in larger cohorts of patients.
Finally, recent reports suggest that PDGFR inhibition may be a therapeutic option for SSc and other fibrotic conditions (41) . Abrogation of V H PAM-V k 16F4-induced collagen gene overexpression by selective mutation of the minimal epitope motif, and inhibition of SSc IgG-induced ROS production and collagen overexpression by use of peptides mimicking the epitope itself, is further corroborating evidence to support the possibility of PDGFR inhibition as a promising new therapeutic strategy against SSc and other pathologic conditions characterized by oxidative stress, fibrosis, and abnormal PDGFR signaling.
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